Journal of Preventive Cardiology
spacer
Current Issue

Review Article

Year: 2016 I  Volume: 6I  Issue: 1I  Pages:954–961
 

Dyslipidemia in children and adolescents

Dr. Peeyush Jain*, MBBS, MD (Med), DM (Cardiology); Sitaraman Radhakrishnan†, MBBS, MD (Med),
DM (Cardiology); Dr. Ashok Seth‡, FRCP (London),
FRCP (Edinburgh), FRCP (Ireland), FACC, FESC, FSCAI (USA), FIMSA, FCSI,
D.Sc. (Honoris Causa), D.Litt (Honoris Causa)
*Director (Cardiology) and Head, Department of Preventive Cardiology, Fortis-Escorts Heart Institute, New Delhi, India
†Director, Department of Pediatric and Fetal Cardiology, Fortis-Escorts Heart Institute, New Delhi, India
‡Chairman, Fortis Escorts Heart Institute; Chairman, Cardiology Council, Fortis Group of Hospitals; Past President, Cardiological Society of India; Vice President, Asian Pacific Society of Cardiology, Member, Medical Council of India

 

Abstract

Some children have genetically determined dyslipidemias that predisposes them to early heart attacks. In addition, dyslipidemias associated with obesity and diabetes mellitus are being increasingly recognized in children and adolescents. Postponing treatment of severely elevated cholesterol until middle-age or late adulthood in both situations may be too late for some children. It is now recommended that all children should be screened for lipids between ages 9 and 11 years and once again between ages 17 and 21 years. Selective screening in other age groups may be desirable if childhood hypertension, diabetes, or obesity is present. Evaluation for a cause is necessary in children with abnormal lipid levels. Severe elevation is likely to be genetic in origin. The mainstay of treatment of high cholesterol levels in children and adolescents is diet and physical activity. No dietary restriction is recommended below 2 years of age. When cholesterol levels are very high and presumed or known to be genetic, children above 8–10 years of age may benefit from statin therapy; however, the dosing should be conservative. Routine health monitoring should include assessment of growth and development and annual liver functions. Bile acid sequestrants and ezetimibe are also approved for children. For homozygous familial hypercholesterolemia (HoFH), the only therapy available is lipoprotein apheresis (LA). LA is presently not available in India. Recently, US Federal Drug Agency has approved mipomersen and lomitapide aimed at reducing cholesterol in HoFH.

 
Keywords
Genetically determined dyslipidemia
Familial hypercholesterolemia
Lipoprotein apheresis
 
[Full Text]
Print this Article
Back to main page
Slideshow
  • State-of-the-Art Article
    Mildly Elevated Blood Pressure: What to do?
    -Dr. Arvind K. Pancholia.
    abstract text full text
  • Original Article
    Heart Failure Entities Peculiar to India
    -Dr. T Govindan Unni
    abstract text full text
  • Original Article
    Saturated Fat: Friend or Foe?
    -Dr. T Govindan Unni
    abstract text full text
  • Update on Statins
    abstract text full text
  • Update on Guidelines
    2018 Guideline on the Management of Blood Cholesterol
    full text
  • Updates on Guidelines
    ACC Consensus on New Diabetes Drugs to Reduce CV Outcomes
    full text
  • News and Views
     
    full text
spacer
Slideshow
  • 2nd World Congress on Cardiac Imaging and Clinical Cardiology 2019
    To be held on Feb 22–24, 2019, Mumbai, India
    Read more...
  • INDIA LIVE 2019
    To be held on Feb 28–Mar 3, 2019,Mumbai
    Read more...
  • Saudi Heart Association 30th Annual Meeting 2019 (SHA 2019)
    To be held on Mar 7–9, 2019, Riyadh, Saudi Arabia
    Read more...
  • American College of Cardiology 68th Annual Scientific Session and Expo
    To be held on Mar 16–18, 2019, New Orleans, LA
    Read more...
  • International Symposium on Endovascular Therapeutics - SITEUpdate 2019
    To be held on Mar 27–29, 2019, Barcelona, Spain
    Read more...
Journal of Preventive Cardiology
spacer
 
spacer
Print ISSN: 2249-4308
Online ISSN: 2277-6559
 
Frequency: Quarterly
 
 
Email This
close
 
 
  [ Separate multiple email addresses with commas (Limit is 10). ]